lead on will provide XXXX. program for at I are order platform be of X as outline a a Capricor in with progress possible. made the XXXX on bring we thank was areas today, exosome DMD as A.J. Capricor for prepared up team our main in lead well and brief Thanks, priorities as To as encouraged Good application commercialization. into assembled to and Capricor biologics we and gearing joining update technology. our to our market today's has main I'm our focused you CAP-XXXX expeditiously call. executing afternoon, treatment that XXXX year have for in the end, product, for CAP-XXXX license as a now big primarily to for And
preparation. BLA each overview an manufacturing, area readiness today. clinical, provide and commercial are I will These of
X:X provide the update and placebo. our enrolled clinical our pivotal Phase United HOPE-X we we First, let me for DMD on trial, ambulant randomized where with III enrollment of trial, across announced last CAP-XXXX HOPE-X Late clinical young pivotal a Phase States. to late-stage men nonambulant completion enrolling year, subjects III XX in
the we futile This interim we December, conducted a who of announce poll were a scores a In continue is on based analysis to otherwise safety was and analysis, DSMB the by futility reached was the to trial. assessment that an recommendation known, with time monitoring not in X-month deemed and blinded successfully of to point course, be prespecified XX the subjects and trial positive board data assessing very the their pleased fashion.
extending our our further $XX and runway. our milestone cash from million triggered of outcome Nippon positive balance Shinyaku important This strengthening first sheet payment
of of fully will Now end the pivotal study XXXX the Cohort for have our quarter know, as as of second of as year Capricor from this clinical at III by you we well A HOPE-X year approximately the Cohort Phase is to a subjects as To B Los of the data enroll which Angeles. enroll our request produced comparable year. to from to that B San designed Diego you, Cohort at This CAP-XXXX is enrolling very XX manufacturing efficacy is FDA remind demonstrate well. in cohort, facility was designed
there are therapeutics few these trials on fact faster in that predicted than non-ambulant approved and based the patients. later-stage clinical even In fact, enrollment has current for very no proceeded partially
limb, upper from skeletal and change the of secondary left as the the is course, various known [ as HOPE-X pull ejection cardiac commonly of endpoint including year, at of primary well ] and performance X version endpoints, The X.X, baseline as ventricular the fraction.
have significant. paper, Phase significant placebo study more HOPE-X the in statistically our a improvements already is improvement the and whether data point relative pull showed changes seen to X.X pole II combination, regions was domains. X.X as in in Even where We and efficacy our that shown endpoints, multiple in statistically showed validating or multiple with Lancet specific
standard gold function. in treated patients saw cardiac treated a CAP-XXXX We X% ventricular with which ejection is improvements patients a saw in fraction, Importantly, measure of left X.XXX. the improvement of p-value
left There improvements are were ventricular need area and left Therefore, and directly DMD. therapeutics address aware of associated with no that of of in and importance this improvements further understated. addition, in systolic the are volume structural the CAP-XXXX that medical approved In in diabolic cannot significant suggesting be ventricular cardiomyopathy there heart. the unmet we
shared to and one The the group [indiscernible] HOPE-X study XXXX. show safety label efficacy of the their continuing the study X-year from treatment extension to open X-year the significant into the year. open-label differences long-term in the as continued in from and of in results last HOPE-X available X.X when will group original quarter decline placebo year of data the patients the we statistically rate have after fourth an second in compared in plan We population have to follow year, we results this to extension patient are
treatment the of of as DMD Further, open-label extension, improvement function the observed by The heart cardiomyopathy of in in in in function fraction, history we measured suggest natural patients. the DMD. a long-term underscore steady decline hope cardiac X-year to results XX% benefits ejection while CAP-XXXX in potential
modeling technologies envision not disease a well, of skipping discussions of set to to exon modification of ability of DMD become rapidly also both muscles gene of strengthen their that allow treatment, by the therapies disease we potentially children disease has robs revenue will because data nature and the the that of and CAP-XXXX an of terrible use for potential our but payer As the a promise garnered orphan modification reimbursement. only this dystrophinopathy. lot long-term because a has multiyear as attention,
current have be other exon a to longer the gene there the further Many for is gene suggests will treatments The of small skipping data with for therapy nothing no attenuation made. along amount of disease gene that be an there albeit potentially for technologies, be DMD, Current need from from relevant with truth. clinical protein microdystrophin therapies thought a therapy. paradigm allows the to approved, progression if are treatment
of will that the by believe require paradigm the address primarily However, consequences lack we and pathological to fibrosis all inflammation dystrophin. multidrug DMD, of of a it caused
in immunomodulation for a is positioned CAP-XXXX be DMD of and stated the fibrosis. to reduction therapy partner mechanism as action perfectly is
at some subjects therapy, but the still inclusion of HOPE-X on are criteria. current study's based exclusion post-gene for qualified fact, and CAP-XXXX In the
shown that that it infusion delays CAP-XXXX has therapies. be preferred is safety profile a If CAP-XXXX hope as exon clinical to of a a trials tolerated. well disease with our be have multiple and strong and progression with CAP-XXXX the demonstrated, skipping once-a-quarter has data treatment or years would gene
to Now program to you goals a and FDA few interactions recent quarters. our next minutes I like on update would several the over take regulatory the for
data year San to data manufacturing Diego we our with aligned A the FDA the program filing used set B and As primary facility. for Phase from design BLA to current last with on the met Cohort the of III Cohort you be our of being may to recall, and transition
enrollment, have the enrolled Cohort to FDA with to BLA. Cohort and Now is we B towards been filing has heading fully continued A expedite discuss of opportunity that the our full and
each outlined FDA. our of action acceptable in of establishment meet Keeping is BLA mechanism between sites. successfully to [indiscernible] by the all acceptance, and marketed the requirements established comparability CMC order assay on to aspect to based the products product, To for is CAP-XXXX mind as manufacturing we our FDA that substantially for end, to in which achieve have critical a potency critical a of that of
and great field approval. helping you leadership of has strategy to of DMD believe with towards to a can on we in the continue work taken CAP-XXXX FDA many forward, treating As a that interest know, move them we move
in doses to now and if our facility by we for our San operational, and can Diego manufacturing facility year CAP-XXXX Diego product San FDA. clinical fully Pharma's use. meet forecast NS of launch, staffed Importantly, produce Currently, X is exceed producing enough approved for
with would I our a expand build would that to a we further potential necessary, demand plans highlight San method-based additional have support BLA or manufacturing larger commercial as also portfolio be relatively acceptance. allowed extended in like We to has capital be of strengthen but to and something operations do patent and know-how. process our investment following IP will forward we small have also Diego expansion our to This facilities us to may to plant. filings place look amount
as We and/or to also drive effectively revenue shares. possible margins are high able revenue control to as on COGS
program to CAP-XXXX Importantly, potentially replicating we manufacturing indications also our modules. our expand can other while
A set as in into we and this time a deliver into puts the of potential according commercial taken we together and in endeavor, I of prepare our position for to for. operations we this DMD. the preparations confident our majority initial feel gone personnel facility can have All that for investment Capricor good product lines have
commercial NS positive, CAP-XXXX potential data actively launch preparing the an assuming for Now who of the BLA. for partnership update and on accepted have is with an we our Pharma, already is
to closer that We work move we with closely continue them goal. as to
profile have positive the supported continuing progression ongoing and commercial we we to first acceptance, very of is which patients by commercial on XXX Therefore, provide stated, As data. report approximately on strong launch a potential CAP-XXXX time pull for a These safety BLA This nearly studies. potential subjects data, are basis. in product. has will participant of would led with expect supportive become full this of patients revenue to open-label This an market slowing the initial already would likely our strong patients. disease combined CAP-XXXX, have on the by stream an will extension be to
strong support partners in to are Pharma. a commercial of early establishing we NS team at the Additionally, stages our
using pursuing of provide like but to briefly useful exosome same surface other for and exosome I'd is we update proprietary platform, that the inside platform Currently, to turn are on the is the therapeutics. engineering our technology. our of X program our on an the select or basic of using avenues is vaccine the opportunity. either One StealthX, development proteins, Now for
containing in text is prepare preventing this use of Diseases, the NextGen, known National structure Allergy of of selected otherwise government's of year with candidate will is The which dose candidates that S, S COVID-XX fund the clinical and Capricor and our major trial. [indiscernible] which for pandemics. a groups as of part I well vaccine, campaign was of will conduct the will low-dose Phase being achievements arrangement X provide high them to for now, and U.S. There a for COVID-XX underway One they the strain as Infectious as the a is the which as future valid nucleocapsid. NIAD, [indiscernible] potential tested, Institute is related then with be vaccine and manufactured fully a current Project
I far we as we as specific be progress to pleased will the the clinical anticipate safety in more for submitted StealthX we of review, terms will is on time hopes candidate IND our am the the efficacy. XXXX. the inform will and this to the only once know, for This have initiate and and we high IND program an FDA as currently I you NIAD approved, lines we year. vaccine, have multivalent is under that success provide in potential which trial through late that tested
II. nicely for it and for a If and program have vaccine while finds consider because for for company, exosome-based supports opportunity criteria fully other a its is intention This safety may vaccine very meets that opportunities. important it Capricor to vaccine up our and become sets efficacy, partnering program focused don't development we NIAT our business Phase the the funded they
and power work of it in a vaccines. as are As with potential efficacy important strategy is program we in StealthX as specific The tissue taking platform appropriately partners more looking involves data target becomes this Each animal protein-based the of the vaccine front, improvement reminder, of a combines forward of preclinical deliver the engineered to a could the are a available. and sharing that with the well suggests and humans arm therapeutic it on works, exosome be using Also data an mRNA early on in to technology potential the our preclinical as technology. then recombinant vaccinology. several this the to very discussions speed a it studies, it Should payload. strategy in develop color important we same exosome
strong by raised And relationship cementing on and approximately our Nippon finally, strategic we year side, equity offering further Capricor. our sheet Shinyaku the into was to and anchored $XX late million corporate financing to an their XXXX. last This balance support commitment
$XX agreement about with you are up that potential through U.S. it XXXX, want with regulatory-based Shinyaku As which to we remind certain of of upon moving to an our think additional time the and into Nippon XXXX approval, payments comes I milestone achievements. million triggered
additional approval, various on milestone Capricor potential is payments, $XXX sales-based be being will there which Following met. based million an potential to payable in targets
we a on will a receive FDA for balance be priority PRB support review the disease for to our DMD, sheet. previous rare our pediatric we or to receive receipt eligible treatment if suit retain which we Furthermore, based of CAP-XXXX help right of the approval would designation, and full look to voucher
CAP-XXXX European Lastly, discussions to we related active in rights DMD. the of with are parties several for
thank support to the balance you partnerships Our your sheet program. leveraging fuel support support. towards nondilutive I and potential for Overall, CAP-XXXX main goal to want approval exosome is to to our continue
manage focus on expeditious our our efforts possible. commercialization to CAP-XXXX in We most bringing continue resources, the potential way diligently towards
very continuing and conferences. we several FDA open-label our interactions looking at to with and various much extension presenting scientific for months be are X-year medical enrollment announcing will We next the forward Cohort data, B investor-related our completing as
over turn financials. to run now call the through will to our I A.J. A.J.?
